NCT06023277View on ClinicalTrials.gov

A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2027

Conditions
Metastatic Breast Cancer
Interventions
BIOLOGICAL

ConvitVax

ConvitVax is a personalized vaccine designed to treat women with breast cancer. The vaccine is composed of three widely commonly used components: autologous tumor cells obtained from the patient's own tumor tissue, BCG D1331, plus a low concentration of formalin.

Trial Locations (3)

1010

Instituto de Oncología Dr. Luis Razetti, Caracas

1071

Fundación Jacinto Convit, Caracas

33069

Jacinto Convit World Organization, Inc., Pompano Beach

All Listed Sponsors
collaborator

Fundación Jacinto Convit

UNKNOWN

collaborator

Instituto Oncologico Luis Razetti

OTHER

lead

Jacinto Convit World Organization Inc.

OTHER